Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAVASOL 8.5% IN PLASTIC CONTAINER vs AMINOSYN 7% W/ ELECTROLYTES
Head-to-head clinical comparison of therapeutic indices and safety profiles.
TRAVASOL 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance in patients unable to tolerate enteral nutrition.
Amino acids are the building blocks for protein synthesis in the body. This solution provides essential and non-essential amino acids to maintain nitrogen balance and support tissue repair and growth when oral intake is inadequate.
Total parenteral nutrition in patients with inadequate oral or enteral intake,Protein calorie malnutrition,Catabolic states (e.g., burns, major surgery, trauma)
Parenteral nutrition for patients unable to obtain adequate nutrition orally or enterally,Nitrogen source in total parenteral nutrition (TPN),Off-label: Adjunct in management of severe catabolic states (e.g., burns, trauma)
Intravenous administration as total parenteral nutrition: typical adult dose is 8.5% amino acid solution at 0.8-1.5 g protein/kg/day, infused continuously or cyclically.
Intravenous infusion at 1-1.5 g amino acids/kg/day. Typical adult dose: 500 m L of 7% solution (35 g amino acids) infused over 8-12 hours, repeated daily as per nitrogen requirements.
Not applicable; constituent amino acids have individual half-lives (e.g., 0.5–2 hours for most L-amino acids) but overall elimination follows zero-order kinetics during continuous infusion. Clinically, infusion rate determines steady-state concentrations.
Terminal elimination half-life for the constituent amino acids ranges from 0.5 to 4 hours, depending on the specific amino acid and metabolic state. Clinically, infusion rate should be adjusted to avoid accumulation in renal impairment.
GFR 30-59 m L/min: reduce to 0.5-0.8 g protein/kg/day; GFR <30 m L/min: 0.4-0.5 g/kg/day; monitor BUN and electrolytes.
GFR <50 m L/min: Reduce to 0.5-0.8 g amino acids/kg/day and monitor BUN. GFR <15 m L/min: Avoid or use with caution, typically not recommended unless on renal replacement therapy.
Not for use in patients with severe hepatic failure, severe uremia, or inborn errors of amino acid metabolism. Risk of hyperammonemia and metabolic acidosis.
Amino acid solutions like TRAVASOL 8.5% are essential for maternal nutrition in pregnancy; however, there are no well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Use during pregnancy only if clearly needed. First trimester: potential risks are not established; avoid unless maternal benefit outweighs unknown fetal risk. Second and third trimesters: may be used cautiously for nutritional support, with monitoring for electrolyte imbalances and fluid overload in the fetus.
Parenteral amino acid solutions are considered essential in pregnancy for maternal and fetal nutrition when oral intake is inadequate. No known teratogenic effects have been reported with standard clinical use. FDA Category C: animal reproduction studies not conducted; potential benefits may warrant use despite potential risks. No evidence of fetal harm in first trimester; continuous IV amino acids may cause metabolic disturbances in fetus (e.g., acidosis, hyperammonemia) if maternal levels are excessive.
TRAVASOL 8.5% is a crystalline amino acid solution used for parenteral nutrition. It contains 8.5% amino acids and provides 85 g protein/L. It is hypertonic (approx. 880 m Osm/L) and must be administered via a central line to avoid thrombophlebitis. Shake container vigorously before use; do not use if cloudy or precipitate present. Do not add medications directly to the plastic container without checking compatibility. Protect from light; do not freeze. Use dedicated IV line without simultaneous blood products due to risk of agglomeration.
Aminosyn 7% w/ Electrolytes is a crystalline amino acid solution used for parenteral nutrition. Monitor serum electrolytes and acid-base balance frequently due to risk of hyperchloremic metabolic acidosis from high chloride content. Adjust infusion rate based on metabolic tolerance and renal function. Contains 50 m Eq/L acetate and 40 m Eq/L chloride; use with caution in patients with renal impairment or hepatic encephalopathy.
No interactions on record
No interactions on record
TRAVASOL 8.5% IN PLASTIC CONTAINER and AMINOSYN 7% W/ ELECTROLYTES are distinct pharmacological agents. TRAVASOL 8.5% IN PLASTIC CONTAINER belongs to the Amino Acid Solution class and is primarily used for Total parenteral nutrition in patients with inadequate oral or enteral intakeProtein calorie malnutritionCatabolic states (e.g., burns, major surgery, trauma). AMINOSYN 7% W/ ELECTROLYTES belongs to the Amino Acid Solution class and is primarily used for Parenteral nutrition for patients unable to obtain adequate nutrition orally or enterallyNitrogen source in total parenteral nutrition (TPN)Off-label: Adjunct in management of severe catabolic states (e.g., burns, trauma). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. TRAVASOL 8.5% IN PLASTIC CONTAINER carries a safety status of Category C, whereas AMINOSYN 7% W/ ELECTROLYTES safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Amino acids are metabolized via deamination, transamination, and oxidative pathways primarily in the liver. Nitrogen is incorporated into urea via the urea cycle.
Amino acids undergo distribution and are primarily metabolized through deamination, transamination, and decarboxylation reactions in the liver and other tissues. The carbon skeletons are used for energy production or gluconeogenesis; the nitrogen is converted to urea in the liver and excreted renally.
Renal elimination of nitrogenous waste products (urea, ammonia) derived from amino acid metabolism; biliary/fecal excretion negligible. In healthy adults, >90% of infused amino nitrogen is ultimately excreted as urea in urine.
Primarily renal. Amino acids are deaminated, and nitrogen is excreted as urea in urine. Biliary/fecal excretion is negligible. Almost 100% of infused amino acids are either metabolized or excreted as urea and other nitrogenous wastes.
Minimal (<10%) for individual amino acids; binding to albumin or other plasma proteins is negligible. Transport is primarily via specific carrier-mediated processes.
Minimal (<5%) for most amino acids; not significantly bound to plasma proteins. Some amino acids (e.g., tryptophan) show moderate albumin binding (~30%), but overall protein binding is negligible.
Approximately 0.3–0.5 L/kg for total amino acids, reflecting distribution into total body water and intracellular compartments. Higher distribution for branched-chain amino acids (leucine, isoleucine, valine) into muscle.
Approximately 0.5-0.8 L/kg, reflecting distribution into total body water. Larger Vd in edematous states; lower in dehydration. Confined to extracellular fluid initially, then intracellular uptake occurs.
Intravenous: 100% (complete). Not administered orally; if taken orally, amino acids are absorbed with bioavailability >90% but first-pass metabolism reduces systemic availability of some (e.g., glutamine, alanine).
Not applicable for oral route. Intravenous bioavailability is 100% by definition.
Child-Pugh Class A: no adjustment; Class B: reduce to 0.6-0.8 g protein/kg/day; Class C: 0.4-0.6 g/kg/day; avoid in hepatic encephalopathy.
Child-Pugh Class B or C: Reduce dose by 50% or use branched-chain amino acid-enriched solutions. Avoid in severe hepatic encephalopathy.
Weight-based: 1.0-2.5 g protein/kg/day intravenously, adjusted for age and clinical status; neonates: 1.5-3.0 g/kg/day.
1-2.5 g amino acids/kg/day by continuous IV infusion. For infants, start at 1 g/kg/day and increase gradually; confirm with total parenteral nutrition guidelines.
Start at lower end of adult range (0.8-1.0 g/kg/day) and titrate based on renal function and metabolic tolerance; monitor fluid and electrolyte balance closely.
Initiate at lower end of adult range (1 g/kg/day) and adjust based on renal function and nutritional status. Monitor fluid balance due to risk of volume overload.
This formulation contains aluminum, which may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are at higher risk because their kidneys are immature, and they require large amounts of calcium/phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including preterm neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. In neonates, aluminum toxicity may be manifested as impaired neurologic development.
There are no direct food interactions as this is an intravenous solution. However, oral food intake is usually restricted or absent during parenteral nutrition therapy. Monitor for refeeding syndrome in severely malnourished patients.
No direct food interactions since administered intravenously. However, oral intake is typically restricted or guided based on underlying condition. Monitor for electrolyte imbalances if concurrent enteral nutrition or oral supplements are used.
TRAVASOL 8.5% is a sterile, hypertonic amino acid solution for intravenous infusion. It is unknown whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when TRAVASOL 8.5% is administered to a nursing woman. The molecular weight of amino acids (< 200 Da) suggests potential for transfer into breast milk, but clinical significance is low due to endogenous presence. M/P ratio: not established.
Amino Syn 7% w/ Electrolytes is compatible with breastfeeding. Exogenous amino acids given intravenously are not known to pose risk to nursing infant. M/P ratio not established; maternal plasma amino acid levels transiently increase but breast milk levels are negligible due to rapid metabolism. Continue breastfeeding while monitoring infant for metabolic acidosis if infant has inborn errors of metabolism (e.g., urea cycle disorders).
No specific dose adjustments are recommended during pregnancy based on pharmacokinetic changes. However, pregnancy increases plasma volume and renal blood flow, potentially altering amino acid clearance. Dose should be individualized based on maternal nutritional status, clinical response, and laboratory monitoring. Avoid overhydration and hyperglycemia. Use with caution in preeclampsia or gestational diabetes.
Pregnancy increases plasma volume and renal blood flow, potentially increasing clearance of amino acids; however, no dose adjustment is typically needed. Monitor for hyperglycemia (pregnancy induces insulin resistance) and adjust glucose in TPN accordingly. No specific dose changes for Amino Syn 7% w/ Electrolytes; base dose on maternal nutritional requirements (e.g., protein 0.8-1.2 g/kg/day in pregnancy).
This medication is given through a vein to provide protein calories when you cannot eat normally.,Your healthcare provider will monitor your blood sugar, kidney, and liver function regularly.,Tell your doctor if you experience fever, chills, flushing, or injection site pain.,Do not stop or adjust the infusion rate without consulting your healthcare team.,If you have diabetes, your blood glucose may rise; follow your management plan.
This medication provides nutrition through a vein; you will be monitored regularly for side effects.,Report any signs of infection at the IV site, such as redness, swelling, or pain.,Tell your healthcare provider if you experience nausea, vomiting, weakness, or confusion.,You may need blood tests to check your kidney and liver function, blood sugar, and electrolyte levels.,Do not stop or change the infusion rate without consulting your healthcare provider.